In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
Silexion Therapeutics Corp (NASDAQ: SLXN) closed the day trading at $1.92 up 10.98% from the previous closing price of $1.73. In other words, the price has increased by $10.98 from its previous closing price. On the day, 0.11 million shares were traded. SLXN stock price reached its highest trading level at $2.0 during the session, while it also had its lowest trading level at $1.6495.
Ratios:
For a better understanding of SLXN, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.97 and its Current Ratio is at 3.97. In the meantime, Its Debt-to-Equity ratio is 0.29 whereas as Long-Term Debt/Eq ratio is at 0.27.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SLXN now has a Market Capitalization of 6003152 and an Enterprise Value of -1214847.
Stock Price History:
The Beta on a monthly basis for SLXN is -0.05, which has changed by -0.94204354 over the last 52 weeks, in comparison to a change of 0.17511821 over the same period for the S&P500. Over the past 52 weeks, SLXN has reached a high of $51.75, while it has fallen to a 52-week low of $1.73. The 50-Day Moving Average of the stock is -31.09%, while the 200-Day Moving Average is calculated to be -77.90%.
Shares Statistics:
Over the past 3-months, SLXN traded about 74.17K shares per day on average, while over the past 10 days, SLXN traded about 51980 shares per day. A total of 3.13M shares are outstanding, with a floating share count of 2.31M. Insiders hold about 26.00% of the company’s shares, while institutions hold 1.14% stake in the company. Shares short for SLXN as of 1765756800 were 78920 with a Short Ratio of 1.06, compared to 1763078400 on 91327. Therefore, it implies a Short% of Shares Outstanding of 78920 and a Short% of Float of 2.55.
Earnings Estimates
The firm’s stock currently is rated by 2.0 analysts.
Analysts are recommending an EPS of between -$3.83 and -$8.24 for the fiscal current year, implying an average EPS of -$6.03. EPS for the following year is -$4.39, with 2.0 analysts recommending between -$3.99 and -$4.8.
